We provide here proof of concept about target engagement for artificial miRNAs to induce long-term tau reduction in human neurons in vitro and in a tauopathy model in vivo, leading to significant improvement in biochemical and phenotypic markers of tau pathology. The gene discussed is MAPT; the disease is tauopathy.